vs
BIOMERICA INC（BMRA）与Lantheus Holdings, Inc.（LNTH）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是BIOMERICA INC的336.2倍（$406.8M vs $1.2M）。Lantheus Holdings, Inc.净利率更高（13.3% vs -109.1%，领先122.4%）。Lantheus Holdings, Inc.同比增速更快（4.0% vs -26.0%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs 4.9%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
BMRA vs LNTH — 直观对比
营收规模更大
LNTH
是对方的336.2倍
$1.2M
营收增速更快
LNTH
高出30.0%
-26.0%
净利率更高
LNTH
高出122.4%
-109.1%
两年增速更快
BMRA
近两年复合增速
4.9%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $406.8M |
| 净利润 | $-1.3M | $54.1M |
| 毛利率 | 4.2% | 59.2% |
| 营业利润率 | -113.5% | 19.0% |
| 净利率 | -109.1% | 13.3% |
| 营收同比 | -26.0% | 4.0% |
| 净利润同比 | -38.9% | 558.8% |
| 每股收益（稀释后） | $-0.45 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRALNTH
| Q4 25 | $1.2M | $406.8M | ||
| Q3 25 | $1.4M | $384.0M | ||
| Q2 25 | $749.0K | $378.0M | ||
| Q1 25 | $1.1M | $372.8M | ||
| Q4 24 | $1.6M | $391.1M | ||
| Q3 24 | $1.8M | $378.7M | ||
| Q2 24 | $1.1M | $394.1M | ||
| Q1 24 | $1.0M | $370.0M |
净利润BMRALNTH
| Q4 25 | $-1.3M | $54.1M | ||
| Q3 25 | $2.0K | $27.8M | ||
| Q2 25 | $-1.5M | $78.8M | ||
| Q1 25 | $-1.2M | $72.9M | ||
| Q4 24 | $-950.0K | $-11.8M | ||
| Q3 24 | $-1.3M | $131.1M | ||
| Q2 24 | $-1.4M | $62.1M | ||
| Q1 24 | $-1.9M | $131.1M |
毛利率BMRALNTH
| Q4 25 | 4.2% | 59.2% | ||
| Q3 25 | 30.7% | 57.9% | ||
| Q2 25 | -33.0% | 63.8% | ||
| Q1 25 | 1.7% | 63.8% | ||
| Q4 24 | 26.7% | 63.5% | ||
| Q3 24 | 16.0% | 63.9% | ||
| Q2 24 | 2.1% | 64.9% | ||
| Q1 24 | -14.7% | 65.4% |
营业利润率BMRALNTH
| Q4 25 | -113.5% | 19.0% | ||
| Q3 25 | -81.0% | 11.4% | ||
| Q2 25 | -209.1% | 23.3% | ||
| Q1 25 | -108.1% | 27.4% | ||
| Q4 24 | -60.7% | 29.1% | ||
| Q3 24 | -75.7% | 35.3% | ||
| Q2 24 | -136.6% | 26.1% | ||
| Q1 24 | -196.7% | 28.8% |
净利率BMRALNTH
| Q4 25 | -109.1% | 13.3% | ||
| Q3 25 | 0.1% | 7.2% | ||
| Q2 25 | -206.1% | 20.8% | ||
| Q1 25 | -103.9% | 19.6% | ||
| Q4 24 | -58.1% | -3.0% | ||
| Q3 24 | -72.8% | 34.6% | ||
| Q2 24 | -127.1% | 15.8% | ||
| Q1 24 | -188.6% | 35.4% |
每股收益（稀释后）BMRALNTH
| Q4 25 | $-0.45 | $0.86 | ||
| Q3 25 | $0.00 | $0.41 | ||
| Q2 25 | $-0.99 | $1.12 | ||
| Q1 25 | $-0.48 | $1.02 | ||
| Q4 24 | $-0.06 | $-0.18 | ||
| Q3 24 | $-0.63 | $1.79 | ||
| Q2 24 | $-2.57 | $0.88 | ||
| Q1 24 | $-0.11 | $1.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $359.1M |
| 总债务越低越好 | — | $568.7M |
| 股东权益账面价值 | $4.4M | $1.1B |
| 总资产 | $6.0M | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资BMRALNTH
| Q4 25 | $2.5M | $359.1M | ||
| Q3 25 | $3.1M | $382.0M | ||
| Q2 25 | $3.1M | $695.6M | ||
| Q1 25 | $3.1M | $938.5M | ||
| Q4 24 | $2.4M | $912.8M | ||
| Q3 24 | $2.8M | $866.4M | ||
| Q2 24 | $4.2M | $757.0M | ||
| Q1 24 | $5.3M | $718.3M |
总债务BMRALNTH
| Q4 25 | — | $568.7M | ||
| Q3 25 | — | $567.9M | ||
| Q2 25 | — | $566.8M | ||
| Q1 25 | — | $566.1M | ||
| Q4 24 | — | $565.3M | ||
| Q3 24 | — | $613.0K | ||
| Q2 24 | — | $563.2M | ||
| Q1 24 | — | $562.5M |
股东权益BMRALNTH
| Q4 25 | $4.4M | $1.1B | ||
| Q3 25 | $5.2M | $1.1B | ||
| Q2 25 | $4.1M | $1.2B | ||
| Q1 25 | $5.5M | $1.2B | ||
| Q4 24 | $5.1M | $1.1B | ||
| Q3 24 | $5.3M | $1.2B | ||
| Q2 24 | $6.6M | $1.0B | ||
| Q1 24 | $7.8M | $945.5M |
总资产BMRALNTH
| Q4 25 | $6.0M | $2.2B | ||
| Q3 25 | $6.9M | $2.3B | ||
| Q2 25 | $5.9M | $2.1B | ||
| Q1 25 | $7.4M | $2.1B | ||
| Q4 24 | $7.3M | $2.0B | ||
| Q3 24 | $7.9M | $2.0B | ||
| Q2 24 | $9.3M | $1.9B | ||
| Q1 24 | $10.3M | $1.8B |
负债/权益比BMRALNTH
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $90.2M |
| 自由现金流经营现金流 - 资本支出 | — | $81.4M |
| 自由现金流率自由现金流/营收 | — | 20.0% |
| 资本支出强度资本支出/营收 | — | 2.2% |
| 现金转化率经营现金流/净利润 | — | 1.67× |
| 过去12个月自由现金流最近4个季度 | — | $354.1M |
8季度趋势，按日历期对齐
经营现金流BMRALNTH
| Q4 25 | $-991.0K | $90.2M | ||
| Q3 25 | $-268.0K | $105.3M | ||
| Q2 25 | $-661.0K | $87.1M | ||
| Q1 25 | $-1.0M | $107.6M | ||
| Q4 24 | $-791.0K | $157.7M | ||
| Q3 24 | $-1.3M | $175.1M | ||
| Q2 24 | $-1.0M | $84.7M | ||
| Q1 24 | $-1.8M | $127.2M |
自由现金流BMRALNTH
| Q4 25 | — | $81.4M | ||
| Q3 25 | — | $94.7M | ||
| Q2 25 | — | $79.1M | ||
| Q1 25 | — | $98.8M | ||
| Q4 24 | — | $141.4M | ||
| Q3 24 | — | $159.3M | ||
| Q2 24 | $-1.1M | $73.5M | ||
| Q1 24 | — | $119.0M |
自由现金流率BMRALNTH
| Q4 25 | — | 20.0% | ||
| Q3 25 | — | 24.7% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 26.5% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 42.0% | ||
| Q2 24 | -95.5% | 18.7% | ||
| Q1 24 | — | 32.2% |
资本支出强度BMRALNTH
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | — | 4.2% | ||
| Q2 24 | 2.1% | 2.8% | ||
| Q1 24 | 0.0% | 2.2% |
现金转化率BMRALNTH
| Q4 25 | — | 1.67× | ||
| Q3 25 | -134.00× | 3.79× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 1.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRA
暂无分部数据
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
